Device Trial Radar · NCT06553625
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 29, 2024
Primary completion
Dec 2035
Study completion Dec 2035
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Aug 14, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.
Conditions
- Parkinson Disease
- Dystonia
- Essential Tremor
- Movement Disorders
Interventions
Radiofrequency AblationDevice
Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in patient's quality of life (QoL) during the study as compared with baselineTime frame: Up to 24-Months
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Uniklinik Köln
Cologne, Germany · Recruiting
Universitaetsklinikum Dusseldorf
Düsseldorf, Germany · Recruiting
Universitaetsklinikum Wuerzburg
Würzburg, Germany · Recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.